



VivaGel[®] Condom: Full Licence Agreement with Durex[®]

Melbourne: 9 September 2008 – Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that a full licence agreement has been signed with SSL International plc (LSE:SSL) in relation to the VivaGel[®] coated condom. SSL manufactures and sells Durex[®] condoms, the market-leading condom brand worldwide.

Under the terms of this agreement SSL secures marketing rights to the VivaGel[®] coated condom in most of the world, including Europe and the USA. Starpharma estimates that its receipts under the agreement will exceed A\$100m comprising royalties on SSL sales, further milestone payments, and development support.

“Given the potential for near term revenue, brand development and the overall size of this opportunity, Starpharma sees the VivaGel[®] coated condom as a key element in our corporate strategy,” said Dr Jackie Fairley, Starpharma’s CEO.

“We are particularly pleased to be working with a company such as SSL, which has the capabilities and marketing strength to rapidly move the product through registration and into the market. This agreement is undoubtedly Starpharma’s most important commercial milestone to date,” Dr Fairley added.

SSL is the world’s leading marketer of condoms with approximately 30% share of the global market for branded condom sales, selling into over 100 countries around the world. Global condom retail sales have been estimated¹ at approximately \$3.2 billion, with the top four companies representing as much as 70% of the market.

Leigh Taylor, Head of Innovation from SSL commented, “VivaGel[®] offers leading edge technology with the potential to enhance our Durex[®] business. We are very pleased to have reached agreement with Starpharma and look forward to working with them to bring the product to market.”

In addition to the VivaGel[®] coated condom, Starpharma continues to develop VivaGel[®] as an applicator-delivered vaginal product for use by women to protect themselves from HIV and HSV-2 (genital herpes).

¹ *Condoms - a global strategic business report 2005*

About SSL International plc:

SSL International plc (LSE:SSL) is a focussed consumer brand company with leading global brands including Durex® condoms, Scholl® footwear and footwear products plus a diverse portfolio of local brands, selling into over 100 countries around the world. Headquartered in the UK, SSL has operations in 35 countries. SSL is the world's largest manufacturer of condoms with approximately 30% share of the global branded condom sales market. Durex has been making condoms of the highest quality for nearly eighty years and has further strengthened its position as the global market leader during the last financial year. The company has enjoyed considerable success in 2007 and 2008 with its innovative line of Durex Play lubricants and sexual enhancement products which have helped to pioneer the acceptance of sexual wellbeing products in mainstream outlets.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

In the wider pharmaceutical field Starpharma has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells). More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio with around 200 patents granted and applications pending - a unique level of IP concentration among nanotechnology companies.

Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

American Depository Receipts (ADRs): Starpharma's ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). The Bank of New York Mellon is the depository bank. Starpharma's ADRs are listed on International OTCQX (www.otcqx.com), a premium market tier in the U.S. for international exchange-listed companies, operated by Pink OTC Markets, Inc.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

For further information:

Media Buchan Consulting		Starpharma www.starpharma.com	
Rebecca Wilson	Ellie Papatthaniou	Dr Jackie Fairley	Ben Rogers
Tel: +61 2 9237 2800 Mob: +61 417 382 391 rwilson@bcg.com.au	Tel: +61 2 9237 2800 epapatthaniou@bcg.com.au	Chief Executive Officer +61 3 8532 2704	Company Secretary +61 3 8532 2702 ben.rogers@starpharma.com